CARDIOVASCULAR JOURNAL OF AFRICA • Vol 24, No 9/10, October/November 2013
AFRICA
e11
References
1.
Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome.
N
Engl J Med
2002;
346
: 752–763.
2.
Meroni PL, Raschi E, Camera M,
et al
. Endothelial activation by aPL: a
potential pathogenetic mechanism for the clinical manifestations of the
syndrome.
J Autoimmun
2000;
15
: 237–240.
3.
Meroni PL, Del Papa N, Raschi E,
et al
.
β
2-Glycoprotein I as a ‘cofac-
tor’ for anti-phospholipid reactivity with endothelial cells.
Lupus
1998;
7
: Suppl 2: S44–S47.
4.
Kandiah DA, Krilis SA. Beta2-glycoprotein I.
Lupus
1994;
3
: 207–212.
5.
Roubey RAS. Tissue factor pathway and the antiphospholipid
syndrome.
J Autoimmun
2000;
15
: 217–220.
6.
Rand JH, Wu X-X, Andree HAM,
et al
. Pregnancy loss in the antiphos-
pholipid-antibody syndrome – a possible thrombogenic mechanism.
N
Engl J Med
1997;
337
:154–160 [Erratum:
N Engl J Med
1997;
337
: 1327.]
7.
Ames PRJ. Antiphospholipid antibodies, thrombosis and atheroscle-
rosis in systemic lupus erythematosus: a unifying ‘membrane stress
syndrome’ hypothesis.
Lupus
1994;
3
: 371–377.
8.
Vaarala O, Alfthan G, Jauhiainen M ,
et al
. Crossreaction between
antibodies to oxidised low-density lipoprotein and to cardiolipin in
systemic lupus erythematosus.
Lancet
1993;
341
: 923–925.
9.
Horkko S, Miller E, Dudl E,
et al
. Antiphospholipid antibodies are
directed against epitopes of oxidized phospholipids: recognition of
cardiolipin by monoclonal antibodies to epitopes of oxidized low
density lipoprotein.
J Clin Invest
1996;
98
: 815–825.
10. Keeling D, Mackie I, Moore G,
et al
. Guidelines on investigation and
management of APS.
Br J Hematol
2012;
157
: 47–58.
11. Miyakis S, Lockshin MD, Atsumi T,
et al
. International consensus
statement on an update of classification criteria for definite APS.
J
Thromb Haemostasis
2005; vol?: 295–306.
12. Petri M. Epidemiology of the antiphospholipid antibody syndrome.
J
Autoimmun
2000;
15
: 145–151.
13. Alarcon-Segovia D, Perez-Vazquez ME, Villa AR, Drenkard C,
Cabiedes J. Preliminary classification criteria for the antiphospholipid
syndrome within systemic lupus erythematosus.
Semin Arthritis Rheum
1992;
21
: 275–286.
14. Adelowo OO, Oguntona S. Antiphospholipid syndrome in Nigeria:
Report of five cases.
East Afr Med J
2009;
86
(2): 94–96.
15. Wilson WA, Perez MC, Michalski JP, Armatis PE. Cardiolipin anti-
bodies and null alleles of C4 in black Americans with systemic lupus
erythematosus.
J Rheumatol
1988;
15
: 1768–1772.
16. Uthman I, Khamashta M. Ethnic and geographical variation in
antiphospholipid (Hughes’) syndrome.
Ann Rheum Dis
2005;
64
:
1671–1676. doi: 10.1136/ard.2005.038448.
17. Diri E, Cucurull E, Gharavi AE,
et al
. Antiphospholipid (Hughes’)
syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is
the most frequent isotype.
Lupus
1999;
8
(4): 263–268.
18. Gonzalez ME, Kahn P, Prize HN,
et al
. Retiform purpura and digital
gangrene secondary to antiphospholipid syndrome successfully treated
with sildenafil.
Arch Dermatol
2011;
147
(2): 164–167.
19. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA.
Antiphospholipid syndrome
. Lancet
2010;
76
(9751): 1498–1509.
20. Asherson RA, Cervera R, Piette J-C,
et al
. Catastrophic antiphospholip-
id syndrome: clinical and laboratory features of 50 patients.
Medicine
(Baltimore)
1998;
77
: 195–207.
